Osiris Therapeutics (OSIR) 13.05 $OSIR
Osiris partners with Arthrex for the exclusive commercialisation and development of the cartilage product Cartiform
M2 - Mon Oct 20, 6:43AM CDT
Regenerative medicine company Osiris Therapeutics (NasdaqGM:OSIR) reported on Friday the launch of an exclusive commercial and development partnership for Cartiform with Arthrex, a medical device company in orthopaedics and sports medicine.
OSIR: 13.05 (+0.04)
Osiris and Arthrex announce an exclusive partnership for the commercialization and development of Cartiform(R)
Business Wire - Fri Oct 17, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive commercial and development partnership for its cartilage product, Cartiform, with Arthrex, Inc. Arthrex is a global medical device company and the leader in new product development and medical education in orthopaedics and sports medicine, operating in over 90 countries throughout the world.
OSIR: 13.05 (+0.04)
Osiris to present three studies on benefits of cryopreserved placental membranes for chronic wounds
Business Wire - Thu Oct 16, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present findings of three wound care related studies this Friday, October 17, at the Symposium on Advanced Wound Care in Las Vegas, Nevada.
OSIR: 13.05 (+0.04)
Osiris Therapeutics Announces Third Quarter 2014 Financial Results Conference Call
Business Wire - Mon Oct 13, 10:57AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for third quarter ended September 30, 2014, on Friday, November 7, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Friday, November 7, 2014, at 9:00 a.m. ET.
OSIR: 13.05 (+0.04)
TEL, XRA, DVR, UYM, QLD, OSIR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Oct 09, 6:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of TE Connectivity Ltd (NYSE:TEL), EXETER RESOURCE CORP (NYSE:XRA), Cal Dive International Inc (NYSE
VR), ProShares Ultra Basic Materials ETF (NYSE:UYM), ProShares Ultra QQQ (NYSE:QLD), Osiris Therapeutics Inc (NASDAQ:OSIR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
QLD: 121.04 (+0.74), XRA: 0.58 (unch), DVR: 0.27 (+0.01), TEL: 54.62 (-0.48), OSIR: 13.05 (+0.04), UYM: 51.82 (+0.87)
Osiris Therapeutics Has Returned 14.6% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Tue Oct 07, 9:53AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 3 months, Osiris Therapeutics has returned 14.56% as of today's recent price of $12.18.
OSIR: 13.05 (+0.04)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.33 (+0.03), DNDN: 1.08 (-0.02), VNDA: 10.30 (+0.11), OSIR: 13.05 (+0.04), CLDN: 10.27 (-0.04), GALE: 1.91 (-0.01), CTIC: 2.37 (unch), OTIC: 23.20 (-0.51)
Osiris Therapeutics Down 10.8% Since SmarTrend Downtrend Call (OSIR)
Comtex SmarTrend(R) - Fri Sep 26, 9:33AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 2 months, Osiris Therapeutics has returned 10.84% as of today's recent price of $12.71.
OSIR: 13.05 (+0.04)
Osiris Therapeutics to Present at the 2014 Stem Cell Meeting on the Mesa
Business Wire - Thu Sep 25, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics and sports medicine markets, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Stem Cell Meeting on the Mesa, on Tuesday, October 7, 2014 at 5:15 p.m. PST in La Jolla, CA.
OSIR: 13.05 (+0.04)
Shares of OSIR Down 11.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 16, 9:16AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 2 months, Osiris Therapeutics has returned 10.98% as of today's recent price of $12.69.
OSIR: 13.05 (+0.04)
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 1.03 (+0.05), PSTI: 2.93 (-0.04), CYTX: 0.47 (-0.01), OSIR: 13.05 (+0.04), NVS: 88.77 (+0.16), CELGZ: 3.57 (-0.14)
Grafix(R) Featured in Plenary Session Oral Presentation at the Joint Annual Meeting of the Eastern and New England Vascular Societies
Business Wire - Mon Sep 15, 3:15PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that data from an evaluation of Grafix in the treatment of chronic venous leg ulcers (VLUs) was presented on Sunday September 14th, at the joint annual meeting of the Eastern Vascular Society and the New England Society for Vascular Surgery.
OSIR: 13.05 (+0.04)
Grafix(R) Randomized Controlled Clinical Trial Recognized as High Quality DFU Trial in Recent Wounds Supplement
Business Wire - Thu Sep 11, 8:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME accredited program entitled Advances In Wound Therapy: Understanding Differences Between Cellular And Acellular Therapies in the Treatment of Chronic Wounds at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
OSIR: 13.05 (+0.04)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
A: 53.37 (-0.63), OSIR: 13.05 (+0.04), ILMN: 179.72 (+0.17), LMNX: 19.84 (+0.12), AFFX: 7.70 (+0.02), QGEN: 22.87 (+0.29), BCOR: 15.60 (+0.23), ACCL: 12.51 (+0.03), ABT: 42.21 (-0.18), INCY: 52.70 (+0.26), BMY: 51.97 (+0.02), WAT: 107.03 (-0.14), ISIS: 41.25 (+0.13), SIAL: 135.77 (+0.17), BASI: 2.39 (-0.01), MRK: 55.27 (+0.14), CGEN: 7.77 (-0.06), CRL: 62.53 (+0.30), CELGZ: 3.57 (-0.14), NVS: 88.77 (+0.16)
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
M2 - Mon Aug 25, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hb86nm/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report to their offering. New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018 The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm The authors. This report provides annualized graft-versus-host disease therapeutics market revenue, cost of therapies and forecasts from 2013 to 2018 across six major markets: the US, France, Germany, Italy, Spain and the UK. Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, clinical trial design, pipeline analysis and competitor evaluations. The report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period. Eirini Vavatsikou, Ph.D., The authors's Analyst covering Immunology, says: Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast's first-to-market Prochymal expected to generate sales of $12.2 million in 2018. Dr. Falk Pharma's Budenofalk is forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively. The authors forecasts that both Jazz Pharmaceuticals' Leukotac and Adienne Pharma's Begedina will enter the GVHD market in 2018, with Leukotac being launched only in the 5EU. Due to their anticipated premium pricing, these drugs are expected to add over $18 million to the 6MM sales by the end of 2018. While multiple biologic products will fall off their respective patent cliffs by the end of the forecast period, Vavatsikou states that this will not impact the GVHD forecast for two important reasons. The analyst explains: Firstly, biosimilar versions of prominent off-label GVHD biologics, such as Rituxan and Campath/Lemtrada, are in very early development and are yet to succeed in clinical trials. Secondly, hematologists across the 6MM are not expected to use biosimilar versions of branded biologics in GVHD patients whose health is already severely compromised. Furthermore, key opinion leaders interviewed by The authors unanimously agreed that they would prefer new biosimilars to be tested in a GVHD clinical trial setting before they use such treatments in the clinic. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Need and Opportunity 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline and Off-Label Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/hb...ityanalyze
JAZZ: 160.60 (+1.25), OSIR: 13.05 (+0.04)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Osiris Therapeutics, Inc. -- OSIR
Business Wire - Thu Aug 14, 9:37AM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential civil securities claims against Osiris Therapeutics, Inc. (NASDAQ:OSIR) resulting from allegations that the Company may have issued materially false statements to investors about the development and progress of its medical products.
OSIR: 13.05 (+0.04)
5 Unusual Stocks Moving on Unusual Volume
at The Street - Tue Aug 12, 8:19AM CDT
Keep these stocks rising on unusual volume on your trading radar.
QUNR: 27.27 (+0.44), MCF: 36.41 (+1.69), OSIR: 13.05 (+0.04), PCLN: 1,134.21 (+1.24), ATHM: 48.94 (-0.13)
Osiris Falls despite Narrower Q2 Loss and Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 10:50AM CDT
Osiris Therapeutics reported second-quarter 2014 loss of 4 cents per share.
ENDP: 64.49 (+0.76), SLXP: 140.86 (+0.31), OSIR: 13.05 (+0.04), ANAC: 28.35 (+0.11)
Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter
Business Wire - Thu Aug 07, 7:03AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the second quarter of 2014.
OSIR: 13.05 (+0.04)
Osiris partners with Arthrex for the exclusive commercialisation and development of the cartilage product Cartiform
M2 - Mon Oct 20, 6:43AM CDT
Regenerative medicine company Osiris Therapeutics (NasdaqGM:OSIR) reported on Friday the launch of an exclusive commercial and development partnership for Cartiform with Arthrex, a medical device company in orthopaedics and sports medicine.
OSIR: 13.05 (+0.04)
Osiris and Arthrex announce an exclusive partnership for the commercialization and development of Cartiform(R)
Business Wire - Fri Oct 17, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive commercial and development partnership for its cartilage product, Cartiform, with Arthrex, Inc. Arthrex is a global medical device company and the leader in new product development and medical education in orthopaedics and sports medicine, operating in over 90 countries throughout the world.
OSIR: 13.05 (+0.04)
Osiris to present three studies on benefits of cryopreserved placental membranes for chronic wounds
Business Wire - Thu Oct 16, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present findings of three wound care related studies this Friday, October 17, at the Symposium on Advanced Wound Care in Las Vegas, Nevada.
OSIR: 13.05 (+0.04)
Osiris Therapeutics Announces Third Quarter 2014 Financial Results Conference Call
Business Wire - Mon Oct 13, 10:57AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for third quarter ended September 30, 2014, on Friday, November 7, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Friday, November 7, 2014, at 9:00 a.m. ET.
OSIR: 13.05 (+0.04)
TEL, XRA, DVR, UYM, QLD, OSIR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Oct 09, 6:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of TE Connectivity Ltd (NYSE:TEL), EXETER RESOURCE CORP (NYSE:XRA), Cal Dive International Inc (NYSE
VR), ProShares Ultra Basic Materials ETF (NYSE:UYM), ProShares Ultra QQQ (NYSE:QLD), Osiris Therapeutics Inc (NASDAQ:OSIR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: QLD: 121.04 (+0.74), XRA: 0.58 (unch), DVR: 0.27 (+0.01), TEL: 54.62 (-0.48), OSIR: 13.05 (+0.04), UYM: 51.82 (+0.87)
Osiris Therapeutics Has Returned 14.6% Since SmarTrend Recommendation (OSIR)
Comtex SmarTrend(R) - Tue Oct 07, 9:53AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 3 months, Osiris Therapeutics has returned 14.56% as of today's recent price of $12.18.
OSIR: 13.05 (+0.04)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.33 (+0.03), DNDN: 1.08 (-0.02), VNDA: 10.30 (+0.11), OSIR: 13.05 (+0.04), CLDN: 10.27 (-0.04), GALE: 1.91 (-0.01), CTIC: 2.37 (unch), OTIC: 23.20 (-0.51)
Osiris Therapeutics Down 10.8% Since SmarTrend Downtrend Call (OSIR)
Comtex SmarTrend(R) - Fri Sep 26, 9:33AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 2 months, Osiris Therapeutics has returned 10.84% as of today's recent price of $12.71.
OSIR: 13.05 (+0.04)
Osiris Therapeutics to Present at the 2014 Stem Cell Meeting on the Mesa
Business Wire - Thu Sep 25, 7:00AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopedics and sports medicine markets, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Stem Cell Meeting on the Mesa, on Tuesday, October 7, 2014 at 5:15 p.m. PST in La Jolla, CA.
OSIR: 13.05 (+0.04)
Shares of OSIR Down 11.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 16, 9:16AM CDT
SmarTrend identified a Downtrend for Osiris Therapeutics (NASDAQ:OSIR) on July 15th, 2014 at $14.26. In approximately 2 months, Osiris Therapeutics has returned 10.98% as of today's recent price of $12.69.
OSIR: 13.05 (+0.04)
Global and Chinese Stem Cell Industry Report, 2014-2017
M2 - Tue Sep 16, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhmz42/global_and) has announced the addition of the "Global and Chinese Stem Cell Industry Report, 2014-2017" report to their offering. Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients. The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out. Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST's adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD). In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter. Key Topics Covered: 1. Overview of Stem Cell Industry 2. Global Stem Cell Industry Chain 3. China Stem Cell Industry Chain 4. Upstream Enterprises 5. Midstream and Downstream Enterprises Companies Mentioned - Advanced Cell Technology - Athersys - Beike Biotechnology - Celgene - Cryo-Cell International - Cryosite - Cyagen Biosciences - Cytori Therapeutics - Esperite - Golden Meditech - LifeCell International - MEDIPOST - Mesoblast - NeoStem - Opexa Therapeutics - Orthofix International - Osiris Therapeutics - Pluristem Therapeutics - Reneuron - StemCells - Tigenix - Vitro Biopharma - ZhongKe Biopharm - Zhongyuan Union Stem Cell Bioengineering For more information visit http://www.researchandmarkets.com/research/hhmz42/global_and
OPXA: 1.03 (+0.05), PSTI: 2.93 (-0.04), CYTX: 0.47 (-0.01), OSIR: 13.05 (+0.04), NVS: 88.77 (+0.16), CELGZ: 3.57 (-0.14)
Grafix(R) Featured in Plenary Session Oral Presentation at the Joint Annual Meeting of the Eastern and New England Vascular Societies
Business Wire - Mon Sep 15, 3:15PM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that data from an evaluation of Grafix in the treatment of chronic venous leg ulcers (VLUs) was presented on Sunday September 14th, at the joint annual meeting of the Eastern Vascular Society and the New England Society for Vascular Surgery.
OSIR: 13.05 (+0.04)
Grafix(R) Randomized Controlled Clinical Trial Recognized as High Quality DFU Trial in Recent Wounds Supplement
Business Wire - Thu Sep 11, 8:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the release of a dedicated supplement in Wounds, a peer-reviewed journal focusing on wound care and wound research, based on the proceedings of a CME accredited program entitled Advances In Wound Therapy: Understanding Differences Between Cellular And Acellular Therapies in the Treatment of Chronic Wounds at the 2014 Spring Symposium on Advanced Wound Care (SAWC) in Orlando.
OSIR: 13.05 (+0.04)
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery A: 53.37 (-0.63), OSIR: 13.05 (+0.04), ILMN: 179.72 (+0.17), LMNX: 19.84 (+0.12), AFFX: 7.70 (+0.02), QGEN: 22.87 (+0.29), BCOR: 15.60 (+0.23), ACCL: 12.51 (+0.03), ABT: 42.21 (-0.18), INCY: 52.70 (+0.26), BMY: 51.97 (+0.02), WAT: 107.03 (-0.14), ISIS: 41.25 (+0.13), SIAL: 135.77 (+0.17), BASI: 2.39 (-0.01), MRK: 55.27 (+0.14), CGEN: 7.77 (-0.06), CRL: 62.53 (+0.30), CELGZ: 3.57 (-0.14), NVS: 88.77 (+0.16)
OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
M2 - Mon Aug 25, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hb86nm/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report to their offering. New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018 The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm The authors. This report provides annualized graft-versus-host disease therapeutics market revenue, cost of therapies and forecasts from 2013 to 2018 across six major markets: the US, France, Germany, Italy, Spain and the UK. Key topics covered include strategic product assessment, market characterization, unmet needs, research and development strategies, clinical trial design, pipeline analysis and competitor evaluations. The report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period. Eirini Vavatsikou, Ph.D., The authors's Analyst covering Immunology, says: Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast's first-to-market Prochymal expected to generate sales of $12.2 million in 2018. Dr. Falk Pharma's Budenofalk is forecast to enter the European GVHD market in 2016, while ATG-Fresenius (ATG-F) will arrive in the US market in 2017. These two products are estimated to achieve 2018 sales of $11,900 and $8 million, respectively. The authors forecasts that both Jazz Pharmaceuticals' Leukotac and Adienne Pharma's Begedina will enter the GVHD market in 2018, with Leukotac being launched only in the 5EU. Due to their anticipated premium pricing, these drugs are expected to add over $18 million to the 6MM sales by the end of 2018. While multiple biologic products will fall off their respective patent cliffs by the end of the forecast period, Vavatsikou states that this will not impact the GVHD forecast for two important reasons. The analyst explains: Firstly, biosimilar versions of prominent off-label GVHD biologics, such as Rituxan and Campath/Lemtrada, are in very early development and are yet to succeed in clinical trials. Secondly, hematologists across the 6MM are not expected to use biosimilar versions of branded biologics in GVHD patients whose health is already severely compromised. Furthermore, key opinion leaders interviewed by The authors unanimously agreed that they would prefer new biosimilars to be tested in a GVHD clinical trial setting before they use such treatments in the clinic. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Need and Opportunity 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline and Off-Label Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/hb...ityanalyze
JAZZ: 160.60 (+1.25), OSIR: 13.05 (+0.04)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Osiris Therapeutics, Inc. -- OSIR
Business Wire - Thu Aug 14, 9:37AM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential civil securities claims against Osiris Therapeutics, Inc. (NASDAQ:OSIR) resulting from allegations that the Company may have issued materially false statements to investors about the development and progress of its medical products.
OSIR: 13.05 (+0.04)
5 Unusual Stocks Moving on Unusual Volume
at The Street - Tue Aug 12, 8:19AM CDT
Keep these stocks rising on unusual volume on your trading radar.
QUNR: 27.27 (+0.44), MCF: 36.41 (+1.69), OSIR: 13.05 (+0.04), PCLN: 1,134.21 (+1.24), ATHM: 48.94 (-0.13)
Osiris Falls despite Narrower Q2 Loss and Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 10:50AM CDT
Osiris Therapeutics reported second-quarter 2014 loss of 4 cents per share.
ENDP: 64.49 (+0.76), SLXP: 140.86 (+0.31), OSIR: 13.05 (+0.04), ANAC: 28.35 (+0.11)
Osiris Therapeutics Announces Second Quarter 2014 Financial Results: Revenue Up 32% Over Previous Quarter
Business Wire - Thu Aug 07, 7:03AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the second quarter of 2014.
OSIR: 13.05 (+0.04)
